<code id='8ECA03C7F7'></code><style id='8ECA03C7F7'></style>
    • <acronym id='8ECA03C7F7'></acronym>
      <center id='8ECA03C7F7'><center id='8ECA03C7F7'><tfoot id='8ECA03C7F7'></tfoot></center><abbr id='8ECA03C7F7'><dir id='8ECA03C7F7'><tfoot id='8ECA03C7F7'></tfoot><noframes id='8ECA03C7F7'>

    • <optgroup id='8ECA03C7F7'><strike id='8ECA03C7F7'><sup id='8ECA03C7F7'></sup></strike><code id='8ECA03C7F7'></code></optgroup>
        1. <b id='8ECA03C7F7'><label id='8ECA03C7F7'><select id='8ECA03C7F7'><dt id='8ECA03C7F7'><span id='8ECA03C7F7'></span></dt></select></label></b><u id='8ECA03C7F7'></u>
          <i id='8ECA03C7F7'><strike id='8ECA03C7F7'><tt id='8ECA03C7F7'><pre id='8ECA03C7F7'></pre></tt></strike></i>

          entertainment

          entertainment

          author:comprehensive    Page View:6
          Mayo Clinic, in Rochester, Minnesota on
          Photo by KEREM YUCEL/AFP via Getty Images

          SAN FRANCISCO — Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first generative AI partner, the health system announced Monday.

          The health system — known for its cutting-edge research and willingness to partner with tech companies — will give Cerebras millions of dollars to help build technology tools based on Mayo’s trove of de-identified patient data, leaders announced at the J.P. Morgan Healthcare Conference. Mayo and Cerebras did not disclose the dollar amount, but Cerebras said it was a multimillion, multi-year contract.

          advertisement

          With roughly 380 employees, Cerebras builds and sells supercomputers specifically designed for AI applications across several industries — pitting the upstart in direct competition with the market leader Nvidia Corp. Life sciences giants including GSK have used its technology for drug discovery, and it has partnered with a health network in United Arab Emirates, but this is Cerebras’ first AI contract with a U.S. health system. The deal gives Mayo access to Cerebras’ supercomputers as well as a Cerebras team to help develop health-tuned models; Mayo will then own whatever they build.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          FDA's naming rule on biosimilars has undermined competition
          FDA's naming rule on biosimilars has undermined competition

          AdobeIrecentlytriedtoorderwhitebloodcellgrowthfactor(pegfilgrastim)biosimilarforoneofmypatients.This

          read more
          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more

          Primary care physicians play key roles in Alzheimer's management

          AdobeWhentheresultsofPresidentBiden’sannualphysicalwerereleasedlastmonth,manywonderedwhyhisprimaryca